Neurotransmitter deficits from frontotemporal lobar degeneration

Murley and Rowe review the neurochemical changes arising from frontotemporal lobar degeneration, including the syndromes frontotemporal dementia, progressive supranuclear palsy and corticobasal degeneration. The evidence base from in vivo and post-mortem human studies, and preclinical models, suggests new strategies to facilitate the development of symptomatic pharmacological treatments, in stratified populations. Abstract Frontotemporal lobar degeneration causes a spectrum of complex degenerative disorders including frontotemporal dementia, progressive supranuclear palsy and corticobasal syndrome, each of which is associated with changes in the principal neurotransmitter systems. We review the evidence for these neurochemical changes and propose that they contribute to symptomatology of frontotemporal lobar degeneration, over and above neuronal loss and atrophy. Despite the development of disease-modifying therapies, aiming to slow neuropathological progression, it remains important to advance symptomatic treatments to reduce the disease burden and improve patients' and carers' quality of life. We propose that targeting the selective deficiencies in neurotransmitter systems, including dopamine, noradrenaline, serotonin, acetylcholine, glutamate and gamma-aminobutyric acid is an important strategy towards this goal. We summarize the current evidence-base for pharmacological treatments and suggest strategies to improve the development of new, effective pharmacological treatments.